Replies to post #27739 on Biotech Values

[spartex]

io io,

Yes, very convincing and detailed presentation, and I really like the depth and relavance of their BOD and Science Advisory Board. Looks like a very streamlined and cost effect approach for getting Proellex and Androxal a high probability for approval by FDA.

I still think the pricing between 11-12 is very attractive for a position. Sure beats DNDN at the moment, and the technicals are also attractive too!